Skip to content
Menu

BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $293

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

BMO Capital analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $292 to $293.

BMO Capital analyst David Lebowitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $292 to $293.

Read at benzinga.com

← All stock news